Cannabidiol (CBD) — the active ingredient in Epidiolex — was found to bind to and block the…
Steve Bryson PhD
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson PhD
Adding Epidiolex, an oral cannabidiol medication, to other treatments successfully stopped epileptic seizures in a boy with…
The add-on anti-seizure therapy Inovelon (rufinamide) shows good tolerability, with one year of treatment not affecting…
Epidiolex (cannabidiol) treatment led to lithium toxicity in a boy with…
The Scottish Medicines Council (SMC) approved Epidyolex (cannabidiol), combined with the anti-epileptic medicine…
Epidiolex, a cannabidiol add-on medication for treatment-resistant epilepsy, was safely given to children…
A single gene therapy treatment using microRNAs improved growth and development, and decreased lethal seizures in…
Mice created with a single mutation found in a person with Lennox-Gastaut syndrome…
Spontaneous mutations affecting a critical protein produced in nerve and muscle cells, called EEF1A2, were found to be the…
A previously unknown inherited variation of a gene linked to Lennox-Gastaut Syndrome (LGS)…